673 |
B-RAF PROTO-ONCOGENE, SERINE/THREONINE KINASE |
BRAF |
B-RAF1 |
B-raf |
BRAF1 |
NS7 |
RAFB1 |
164757 |
1097 |
ENSG00000157764 |
OTTHUMG00000157457 |
P15056 |
PA25408 |
v-raf murine sarcoma viral oncogene homolog B1 |
B-RAF PROTO-ONCOGENE SERINE/THREONINE-PROTEIN KINASE (EC 2.7.1.37) (P94) (V-RAF MURINE SARCOMA VIRAL ONCOGENE HOMOLOG B1). [SOURCE:UNIPROT/SWISSPROT;ACC:P15056] |
p94 |
Proto-oncogene B-Raf |
Serine/threonine-protein kinase B-raf |
TTDS00346 |
B-RAF PROTEIN |
BRAF SERINE/THREONINE KINASE |
BRAF(V599E) |
B-RAF PROTO-ONCOGENE SERINE/THREONINE-PROTEIN KINASE |
1943 |
NP_004324 |
NM_004333 |
5 |
BE0000634 |
BRAF1_HUMAN |
BRAF_HUMAN |
RAF |
Target Class | Enzymes |
Target Subclass | EC:2.7.11.1 |
Has Variant Annotation | false |
Is VIP | false |
Human Readable Name | DRUGGABLE GENOME |
Gene Biotype | PROTEIN_CODING" |
Human Readable Name | SERINE THREONINE KINASE |
GuideToPharmacology Gene Category Name | RAF family |
GuideToPharmacology Gene Category ID | 610 |
GuideToPharmacology Gene Type | enzyme |
Target Subclass | 2.7.11.1 |
Target Main Class | Enzymes |
CancerCommons Reported Gene Name | BRAF (V660) E/K |
CancerCommons Reported Gene Name | BRAF |
CancerCommons Reported Gene Name | Pan-RAF |
CancerCommons Reported Gene Name | BRAF V600E |
Interpro Short Name | Ser-Thr/Tyr_kinase_cat_dom |
Interpro Name | Serine-threonine/tyrosine-protein kinase catalytic domain |
Uniprot Evidence | 1: Evidence at protein level |
Interpro Acc | IPR001245 |
Uniprot Status | Swiss-Prot |
Interpro Type | Domain |
Human Readable Name | KINASE |
Source Reported Gene Name | BRAF |
Gene Category | CLINICALLY ACTIONABLE |
inhibitor |
Details of the Assay for Interaction | Inhibition of wild type BRAF kinase domain (aa416-766) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
inhibitor |
Details of the Assay for Interaction | Inhibition of wild type BRAF activity. |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
inhibitor |
Trial Name | CHIR-265 |
Novel drug target | Established target |
Specific Action of the Ligand | Inhibition |
inhibitor |
Indication/Tumor Type | non-small cell lung carcinoma |
Response Type | resistant |
Approval Status | Preclinical - Pdx |
inhibitor |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor |
Drug family | BRAF inhibitor |
Alteration | BRAF:V600E |
Specific Action of the Ligand | Inhibition |
inhibitor |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | True |
inhibitor |
Details of the Assay for Interaction | In a cell-free assay |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
inhibitor |
Notes | |
combination therapy | LGX818 + Cetuximab + BYL719 |
Indication/Tumor Type | colorectal cancer |
inhibitor |
Drug family | BCR-ABL inhibitor 2nd gen |
Alteration | BRAF:Y472C |
Alteration | BRAF:G466V |
inhibitor |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor |
Trial Name | XL281 |
Novel drug target | Established target |
Mechanism of Interaction | Serine/threonine-protein kinase B-raf inhibitor |
inhibitor |
Mechanism of Interaction | Serine/threonine-protein kinase B-raf inhibitor |
Direct Interaction | yes |
Notes | Targets wildtype BRAF and BRAF with V600E mutation |
inhibitor |
Reported Cancer Type | Melanoma |
Mechanism of Interaction | Serine/threonine-protein kinase B-raf inhibitor |
Direct Interaction | yes |
inhibitor |
Trial Name | GSK2118436 |
Novel drug target | Established target |
inhibitor |
Mechanism of Interaction | Serine/threonine-protein kinase B-raf inhibitor |
Direct Interaction | yes |
inhibitor |
Mechanism of Interaction | RAF serine/threonine protein kinase inhibitor |
Direct Interaction | yes |
Indication/Tumor Type | Advanced Solid Tumor |
inhibitor |
Mechanism of Interaction | Serine/threonine-protein kinase B-raf inhibitor |
Direct Interaction | yes |
inhibitor |
Mechanism of Interaction | Serine/threonine-protein kinase B-raf inhibitor |
Direct Interaction | yes |
inhibitor |
combination therapy | Dabrafenib;Trametinib |
Drug family | BRAF inhibitor;MEK inhibitor |
Alteration | BRAF:V600E |
inhibitor |
combination therapy | Sorafenib + Temsirolimus |
Trial Name | Nexavar |
Novel drug target | Established target |
inhibitor |
Trial Name | PLX4032, RG7204 |
Novel drug target | Established target |
Drug family | BRAF inhibitor |
inhibitor |
combination therapy | Bevacizumab + Temsirolimus + Doxil |
Indication/Tumor Type | ovarian carcinoma |
Response Type | sensitive |
n/a |
Indication/Tumor Type | melanoma |
Response Type | no benefit |
Approval Status | Preclinical |
n/a |
combination therapy | Selumetinib + Paclitaxel |
Drug family | MEK inhibitor |
Alteration | BRAF__. |
n/a |
combination therapy | Encorafenib + Binimetinib + Cetuximab |
combination therapy | Binimetinib + BKM120 |
Indication/Tumor Type | melanoma |
n/a |
Indication/Tumor Type | colorectal cancer |
Response Type | resistant |
Approval Status | Preclinical |
n/a |
combination therapy | Pimasertib + Sorafenib |
Indication/Tumor Type | colorectal cancer |
Response Type | sensitive |
n/a |
combination therapy | Panitumumab;Dabrafenib;BYL719 |
Drug family | EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor |
Alteration | BRAF:V600. |
n/a |
combination therapy | GDC0879 + GDC-0941 |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
n/a |
combination therapy | Vemurafenib + Gefitinib |
Indication/Tumor Type | colorectal cancer |
Response Type | sensitive |
n/a |
combination therapy | BEZ235 + Vemurafenib |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
n/a |
combination therapy | Cetuximab + Irinotecan |
Indication/Tumor Type | colorectal cancer |
Response Type | resistant |
n/a |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
Approval Status | Phase I |
n/a |
Indication/Tumor Type | colorectal cancer |
Response Type | sensitive |
Approval Status | Preclinical |
n/a |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
Approval Status | Phase I |
n/a |
combination therapy | Binimetinib + BKM120 |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
n/a |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
Approval Status | Preclinical - Cell culture |
n/a |
combination therapy | Everolimus + Selumetinib |
Indication/Tumor Type | malignant glioma |
Response Type | predicted – sensitive |
n/a |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
Approval Status | Guideline |
n/a |
combination therapy | Fluorouracil + Leucovorin + Trastuzumab |
Indication/Tumor Type | rectum adenocarcinoma |
Response Type | no benefit |
n/a |
combination therapy | Fluorouracil + Leucovorin + Trastuzumab |
Indication/Tumor Type | rectum adenocarcinoma |
Response Type | no benefit |
n/a |
combination therapy | Fluorouracil + Leucovorin + Trastuzumab |
Indication/Tumor Type | rectum adenocarcinoma |
Response Type | no benefit |
n/a |
combination therapy | PF3644022 + PF-477736 |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | predicted – sensitive |
n/a |
combination therapy | PF3644022 + PF-477736 |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | predicted – sensitive |
n/a |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | sensitive |
Approval Status | Preclinical |
n/a |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
Approval Status | Preclinical |
n/a |
combination therapy | Lapatinib + Panobinostat |
Indication/Tumor Type | colorectal cancer |
Response Type | sensitive |
n/a |
combination therapy | Lapatinib + Panobinostat |
Indication/Tumor Type | colorectal cancer |
Response Type | sensitive |
n/a |
Indication/Tumor Type | skin melanoma |
Response Type | sensitive |
Approval Status | Preclinical - Cell line xenograft |
n/a |
combination therapy | PLX4720 + Tivozanib |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
n/a |
combination therapy | Trametinib + TW-37 |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
n/a |
combination therapy | PLX4720 + Doxorubicin |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
n/a |
Indication/Tumor Type | glioblastoma multiforme |
Response Type | sensitive |
Approval Status | Preclinical - Cell culture |
n/a |
combination therapy | Dabrafenib + GSK2126458 |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
n/a |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
Approval Status | Preclinical |
n/a |
combination therapy | Trametinib + Navitoclax |
Indication/Tumor Type | non-small cell lung carcinoma |
Response Type | sensitive |
n/a |
combination therapy | Cediranib + Selumetinib + PLX4720 |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
n/a |
Indication/Tumor Type | colon cancer |
Response Type | sensitive |
Approval Status | Preclinical |
n/a |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
Approval Status | Preclinical |
n/a |
combination therapy | Encorafenib + Ribociclib |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
n/a |
combination therapy | Erlotinib + PLX4720 |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
n/a |
combination therapy | BI 882370 + Afatinib |
Indication/Tumor Type | colorectal cancer |
Response Type | sensitive |
n/a |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
Approval Status | Preclinical - Cell culture |
n/a |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
Approval Status | Preclinical - Cell line xenograft |
n/a |
combination therapy | PLX4720 + Vorinostat |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
n/a |
combination therapy | DT01 + Fluorouracil + Oxaliplatin |
Indication/Tumor Type | colorectal cancer |
Response Type | sensitive |
n/a |
combination therapy | ARQ092 + Trametinib |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
n/a |
Indication/Tumor Type | colorectal cancer |
Response Type | sensitive |
Approval Status | Preclinical |
n/a |
combination therapy | PLX3397 + Vemurafenib |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
n/a |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
Approval Status | Preclinical - Cell line xenograft |
n/a |
combination therapy | GSK2636771 + unspecified PD-1 antibody |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
n/a |
Indication/Tumor Type | melanoma |
Response Type | no benefit |
Approval Status | Preclinical |
n/a |
combination therapy | Vemurafenib + ZSTK474 |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
n/a |
Indication/Tumor Type | melanoma |
Response Type | no benefit |
Approval Status | Preclinical |
n/a |
combination therapy | Venetoclax + VX-11e |
Indication/Tumor Type | colorectal cancer |
Response Type | no benefit |
n/a |
Indication/Tumor Type | non-small cell lung carcinoma |
Response Type | sensitive |
Approval Status | Preclinical |
n/a |
Indication/Tumor Type | collecting duct carcinoma |
Response Type | sensitive |
Approval Status | Preclinical - Pdx |
n/a |
combination therapy | AZD6482 + NVP-AEW541 |
Indication/Tumor Type | melanoma |
Response Type | no benefit |
n/a |
combination therapy | AZD6482 + NVP-AEW541 |
Indication/Tumor Type | melanoma |
Response Type | no benefit |
n/a |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | sensitive |
Approval Status | Preclinical |
n/a |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
Approval Status | Preclinical |
n/a |
combination therapy | E6201 + LY294002 |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
n/a |
combination therapy | ABT-263 + CGM097 + Dabrafenib + PF-04217903 |
Indication/Tumor Type | colorectal cancer |
Response Type | sensitive |
n/a |
combination therapy | SAR260301 + Selumetinib |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
n/a |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
Approval Status | Preclinical - Cell culture |
n/a |
combination therapy | MK2206 + Trametinib |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
n/a |
combination therapy | Bevacizumab + Temsirolimus + Doxil |
Indication/Tumor Type | ovarian carcinoma |
Response Type | sensitive |
n/a |
Indication/Tumor Type | breast cancer |
Response Type | decreased response |
Approval Status | Preclinical - Cell line xenograft |
n/a |
combination therapy | Crizotinib;Vemurafenib |
Drug family | ALK inhibitor;BRAF inhibitor |
Alteration | MET:amp;BRAF:V600E |
n/a |
combination therapy | Vemurafenib + Voruciclib |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
n/a |
combination therapy | Atezolizumab + Vemurafenib + Cobimetinib |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
n/a |
n/a |
combination therapy | Dabrafenib;Trametinib |
Drug family | BRAF inhibitor;MEK inhibitor |
Alteration | BRAF:V600E |
n/a |
combination therapy | Panitumumab;Dabrafenib;BYL719 |
Drug family | EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor |
Alteration | BRAF:V600. |
n/a |
Drug family | EGFR mAb inhibitor |
Alteration | BRAF:V600E |
combination therapy | Dabrafenib + Cetuximab |
n/a |
combination therapy | Vemurafenib;Cobimetinib |
Drug family | BRAF inhibitor;MEK inhibitor |
Alteration | BRAF:V600E,V600K |
n/a |
combination therapy | Selumetinib + Paclitaxel |
n/a |
BRAF | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING" |
673 | Entrez Gene Id |
BRAF | Gene Symbol |
Human Readable Name | SERINE THREONINE KINASE |
BRAF | Gene Symbol |
Target Class | Enzymes |
Target Subclass | EC:2.7.11.1 |
B-RAF PROTO-ONCOGENE SERINE/THREONINE-PROTEIN KINASE (EC 2.7.1.37) (P94) (V-RAF MURINE SARCOMA VIRAL ONCOGENE HOMOLOG B1). [SOURCE:UNIPROT/SWISSPROT;ACC:P15056] | Description |
BRAF | Display Id |
ENSG00000157764 | Ensembl Gene Id |
Human Readable Name | DRUGGABLE GENOME |
673 | Entrez Gene Id |
BRAF | Gene Symbol |
P15056 | Uniprot Accession |
Target Subclass | 2.7.11.1 |
Target Main Class | Enzymes |
673 | Entrez Gene ID |
Source Reported Gene Name | BRAF |
Gene Category | CLINICALLY ACTIONABLE |
673 | Entrez Gene ID |
CancerCommons Reported Gene Name | BRAF (V660) E/K |
CancerCommons Reported Gene Name | BRAF |
CancerCommons Reported Gene Name | Pan-RAF |
BRAF | Uniprot Gene Name |
P15056 | Uniprot Accession |
ENSG00000157764 | Ensembl Gene Id |
Interpro Short Name | Ser-Thr/Tyr_kinase_cat_dom |
Interpro Name | Serine-threonine/tyrosine-protein kinase catalytic domain |
Uniprot Evidence | 1: Evidence at protein level |
673 | Entrez Gene ID |
P15056 | SwissProt Accession |
NP_004324 | RefSeq Protein Accession |
GuideToPharmacology Gene Category Name | RAF family |
GuideToPharmacology Gene Category ID | 610 |
GuideToPharmacology Gene Type | enzyme |
v-raf murine sarcoma viral oncogene homolog B1 | Gene Name |
ENSG00000157764 | Ensembl Gene Id |
673 | Entrez Gene Id |
Has Variant Annotation | false |
Is VIP | false |
B-RAF1 | OncoKB Gene Synonym |
RAFB1 | OncoKB Gene Synonym |
BRAF1 | OncoKB Gene Synonym |
5 | CIViC Gene ID |
673 | Entrez Gene ID |
RAFB1 | CKB Gene Synonym |
NS7 | CKB Gene Synonym |
BRAF1 | CKB Gene Synonym |
ENSG00000157764 | Ensembl Gene Id |
673 | Entrez Gene Id |
P15056 | UniProt Accession |
P15056 | UniProtKB ID |
B-Raf proto-oncogene, serine/threonine kinase | GuideToPharmacology Name |
BRAF | Ensembl Id |
ENSG00000157764 | Gene Symbol |
BRAF | Gene Symbol |
RAFB1 | GO Gene Synonym |
BRAF1 | GO Gene Synonym |
BRAF_HUMAN | GO Gene Synonym |
v-raf murine sarcoma viral oncogene homolog B1 | Gene Synonym |
ENSG00000157764 | Ensembl Gene Id |
673 | Entrez Gene Id |
RAF | MyCancerGenome Reported Gene Name |
BRAF | MyCancerGenome Reported Gene Name |
BRAF | MyCancerGenome Gene Symbol |
BRAF1 | GENE_SYMBOL |
v-Raf murine sarcoma viral oncogene homolog B1 | UNIPROT |
p94 | UNIPROT |